{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05865041",
            "orgStudyIdInfo": {
                "id": "ASLAN003-004"
            },
            "organization": {
                "fullName": "ASLAN Pharmaceuticals",
                "class": "OTHER"
            },
            "briefTitle": "Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants",
            "officialTitle": "A Parallel Group Treatment, Phase 2a, Double-blind, Two-arm Study to Investigate the Efficacy and Safety of Farudodstat Tablets Compared With Its Placebo in Male or Female Alopecia Areata Participants Aged 18 Years and Older With 30% or Greater Scalp Hair Loss",
            "acronym": "FAST-AA",
            "therapeuticArea": [
                "Other"
            ],
            "study": "investigate-the-efficacy-and-safety-of-farudodstat-compared-with-its-placebo-in-adult-alopecia-areata-participants"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-12",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-04-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-10-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-04-15",
            "studyFirstSubmitQcDate": "2023-05-09",
            "studyFirstPostDateStruct": {
                "date": "2023-05-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-12-12",
            "lastUpdatePostDateStruct": {
                "date": "2023-12-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "ASLAN Pharmaceuticals",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The main purpose of this study is to measure the efficacy of farudodstat compared to placebo at Week 12 from the treatment start, in adult participants with Alopecia Areata (AA) with 30% or greater scalp hair loss."
        },
        "conditionsModule": {
            "conditions": [
                "Alopecia Areata"
            ],
            "keywords": [
                "farudodstat",
                "alopecia areata",
                "DHODH inhibitor",
                "ASLAN003"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "interventionModelDescription": "Approximately 60 participants will be randomized in into one of two treatment sequences:\n\n* Sequence one: Farudodstat 100mg twice daily for 12 weeks followed by placebo twice daily for 12 weeks\n* Sequence two: Placebo twice daily for 12 weeks followed by farudodstat 100mg twice daily for 12 weeks",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Farudodstat for 12 weeks followed by placebo for 12 weeks",
                    "type": "EXPERIMENTAL",
                    "description": "Farudodstat 100mg twice daily for 12 weeks followed by matching Placebo twice daily for 12 weeks",
                    "interventionNames": [
                        "Drug: Farudodstat",
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Placebo for 12 weeks followed by farudodstat for 12 weeks",
                    "type": "EXPERIMENTAL",
                    "description": "Matching Placebo twice daily for 12 weeks followed by farudodstat 100mg twice daily for 12 weeks",
                    "interventionNames": [
                        "Drug: Farudodstat",
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Farudodstat",
                    "description": "Farudodstat tablets administered orally",
                    "armGroupLabels": [
                        "Farudodstat for 12 weeks followed by placebo for 12 weeks",
                        "Placebo for 12 weeks followed by farudodstat for 12 weeks"
                    ],
                    "otherNames": [
                        "ASLAN003"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo tablets administered orally",
                    "armGroupLabels": [
                        "Farudodstat for 12 weeks followed by placebo for 12 weeks",
                        "Placebo for 12 weeks followed by farudodstat for 12 weeks"
                    ],
                    "otherNames": [
                        "Placebo Comparator"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percentage of change from baseline in Severity of Alopecia Tool (SALT) score at Week 12 from the treatment start.",
                    "description": "The Severity of Alopecia Tool (SALT) is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).",
                    "timeFrame": "Treatment Start to Week 12"
                },
                {
                    "measure": "Incidence of adverse events (AEs) up to Week 28",
                    "timeFrame": "Treatment Start to Week 28"
                },
                {
                    "measure": "Number of participants with clinically significant laboratory parameters",
                    "timeFrame": "Treatment Start to Week 28"
                },
                {
                    "measure": "Number of participants with clinically significant Electrocardiogram (ECG) parameters",
                    "timeFrame": "Treatment Start to Week 28"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change from baseline in Severity of Alopecia Tool (SALT) score at Week 12 from the treatment start.",
                    "description": "The Severity of Alopecia Tool (SALT) is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).",
                    "timeFrame": "Treatment Start to Week 12"
                },
                {
                    "measure": "Proportion of participants achieving Severity of Alopecia Tool (SALT) \u226420 at Week 12 from the treatment start.",
                    "description": "The Severity of Alopecia Tool (SALT) is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).",
                    "timeFrame": "Treatment Start to Week 12"
                },
                {
                    "measure": "Proportion of participants achieving 50% Improvement of Severity of Alopecia Tool (SALT) (SALT50) at Week 12 from the treatment start.",
                    "description": "The Severity of Alopecia Tool (SALT) is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).",
                    "timeFrame": "Treatment Start to Week 12"
                },
                {
                    "measure": "Time to Severity of Alopecia Tool (SALT) score improvement of 50% by Week 12 from the treatment start.",
                    "description": "The Severity of Alopecia Tool (SALT) is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).",
                    "timeFrame": "Treatment Start to Week 12"
                },
                {
                    "measure": "Proportion of participants achieving 75% Improvement of Severity of Alopecia Tool (SALT) (SALT75) at Week 12 from the treatment start.",
                    "description": "The Severity of Alopecia Tool (SALT) is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).",
                    "timeFrame": "Treatment Start to Week 12"
                },
                {
                    "measure": "Time to Severity of Alopecia Tool (SALT) score improvement of 75% by Week 12 from the treatment start.",
                    "description": "The Severity of Alopecia Tool (SALT) is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).",
                    "timeFrame": "Treatment Start to Week 12"
                },
                {
                    "measure": "Proportion of participants with Scalp Hair Assessment Patient Reported Outcome (PRO)\u2122 score of 0 or 1 with a \u22652-point improvement at Week 12 from the treatment start among participants with a score of \u22653 at baseline.",
                    "description": "Participants will assess the severity of their scalp hair loss using 5-point Scalp Hair Assessment PRO\u2122\ufe0f scale (0-4) with 4 being the most scalp hair loss",
                    "timeFrame": "Treatment Start to Week 12"
                },
                {
                    "measure": "Proportion of participants achieving Clinician Reported Outcome (ClinRO) measure for Eyebrow Hair Loss\u2122 0 or 1 with \u22652-point improvement from baseline (Among Participants with scores \u22652 at Baseline) at Week 12 from the treatment start.",
                    "description": "ClinRO is scored from 0 to 3 with the 3 representing the most eyebrow hair loss.",
                    "timeFrame": "Treatment Start to Week 12"
                },
                {
                    "measure": "Proportion of participants achieving Clinician Reported Outcome (ClinRO) measure for Eyelash Hair Loss\u2122 0 or 1 with \u22652-point improvement from baseline (among participants with scores \u22652 at baseline) at Week 12 from the treatment start.",
                    "description": "ClinRO is scored from 0 to 3 with the 3 representing the most eyelash hair loss.",
                    "timeFrame": "Treatment Start to Week 12"
                },
                {
                    "measure": "Proportion of participants achieving Patient Reported Outcome (PRO) Measure for Eyebrows\u2122 0 or 1 with \u22652-point improvement from baseline (among participants with scores \u22652 at baseline) at Week 12 from the treatment start.",
                    "description": "Patient's self-assessment of the overall severity of eyebrow hair loss is measured by a 4-point scale (0-3) with photoguide with 3 being the most eyebrow hair loss.",
                    "timeFrame": "Treatment Start to Week 12"
                },
                {
                    "measure": "Proportion of participants achieving Patient Reported Outcome (PRO) Measure for Eyelashes\u2122 0 or 1 with \u22652-point improvement from baseline (among participants with scores \u22652 at Baseline) at Week 12 from the treatment start.",
                    "description": "Patient's self-assessment of the overall severity of eyelash hair loss is measured by a 4-point scale (0-3) with photoguide with 3 being the most eyelash hair loss.",
                    "timeFrame": "Treatment Start to Week 12"
                },
                {
                    "measure": "Proportion of participants achieving any amount of hair regrowth at Week 12 after treatment start among participants with alopecia totalis/alopecia universalis (AT/AU)",
                    "timeFrame": "Treatment Start to Week 12"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult (\u226518 years of age and a weight of \u226540 kg at the time of signing the informed consent)\n* Moderate, severe, or very severe Alopecia Areata (AA), as determined by meeting the following criteria:\n\n  1. Clinical diagnosis of AA with no other etiology of hair loss (e.g., telogen effluvium, androgenetic alopecia, etc.)\n  2. At least 30% scalp hair loss, as defined by a SALT score \u226530\n  3. Current episode of hair loss lasting at least 6 months and not exceeding 7 years at the time of Screening. Participants who have AA for longer than 7 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 7 years\n  4. No appreciable change (i.e., change exceeding 20 points on SALT score) in terminal hair regrowth within 6 months\n\nExclusion Criteria:\n\n* Known history of androgenic alopecia or female pattern hair loss prior to AA\n* Other types of alopecia (including, but not limited to traction and scarring alopecia, telogen effluvium, diffuse type of AA)\n* History or presence of hair transplants\n* Other scalp disease that may impact AA assessment or require topical treatment (including, but not limited to scalp psoriasis, seborrheic dermatitis, actinic keratosis)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "ASLAN Pharmaceuticals",
                    "role": "CONTACT",
                    "phone": "+65 6817 9598",
                    "email": "contact@aslanpharma.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Chief Medical Officer",
                    "affiliation": "ASLAN Pharmaceuticals",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35205",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "Fountain Valley",
                    "state": "California",
                    "zip": "92708",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.70918,
                        "lon": -117.95367
                    }
                },
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "Santa Ana",
                    "state": "California",
                    "zip": "92701",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.74557,
                        "lon": -117.86783
                    }
                },
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06519",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                },
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "Washington",
                    "state": "District of Columbia",
                    "zip": "20037",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.89511,
                        "lon": -77.03637
                    }
                },
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "Coral Gables",
                    "state": "Florida",
                    "zip": "33134",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.72149,
                        "lon": -80.26838
                    }
                },
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46250",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                },
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40241",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                },
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "Brighton",
                    "state": "Massachusetts",
                    "zip": "02135",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.3501,
                        "lon": -71.15644
                    }
                },
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "Minneapolis",
                    "state": "Minnesota",
                    "zip": "55455",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.97997,
                        "lon": -93.26384
                    }
                },
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "New Brighton",
                    "state": "Minnesota",
                    "zip": "55112",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.06552,
                        "lon": -93.20189
                    }
                },
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "Saint Joseph",
                    "state": "Missouri",
                    "zip": "64506",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.76861,
                        "lon": -94.84663
                    }
                },
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "Omaha",
                    "state": "Nebraska",
                    "zip": "68114",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.25626,
                        "lon": -95.94043
                    }
                },
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "Columbus",
                    "state": "Ohio",
                    "zip": "43215",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.96118,
                        "lon": -82.99879
                    }
                },
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37215",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "Pflugerville",
                    "state": "Texas",
                    "zip": "78660",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.43937,
                        "lon": -97.62
                    }
                },
                {
                    "facility": "2 Sites",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78218",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "1 Site",
                    "status": "RECRUITING",
                    "city": "Webster",
                    "state": "Texas",
                    "zip": "77598",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fastaa@aslanpharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.53773,
                        "lon": -95.11826
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000505",
                    "term": "Alopecia"
                },
                {
                    "id": "D000000506",
                    "term": "Alopecia Areata"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007039",
                    "term": "Hypotrichosis"
                },
                {
                    "id": "D000006201",
                    "term": "Hair Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000020763",
                    "term": "Pathological Conditions, Anatomical"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3846",
                    "name": "Alopecia",
                    "asFound": "Alopecia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3847",
                    "name": "Alopecia Areata",
                    "asFound": "Alopecia Areata",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10089",
                    "name": "Hypotrichosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M9293",
                    "name": "Hair Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22519",
                    "name": "Pathological Conditions, Anatomical",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}